Back to School: How biopharma can reboot drug development. Access exclusive analysis here

HS-tk vector injected into tumor cells to express the gene for thymidine kinase: Began a Phase I/II trial with partner Sandoz Pharma Ltd. in six patients, with

Genetic Therapy Inc. (GTII), Gaithersburg,

Read the full 57 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE